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Abstract
Background: Coxsackievirus A9 (CV-A9) is a pathogenic enterovirus type within the family Picornaviridae. CV-A9
infects A549 human epithelial lung carcinoma cells by attaching to the αVβ6 integrin receptor through a highly
conserved Arg-Gly-Asp (RGD) motif, which is located at the exposed carboxy-terminus of the capsid protein VP1
detected in all studied clinical isolates. However, genetically-modified CV-A9 that lacks the RGD motif (CV-A9-
RGDdel) has been shown to be infectious in some cell lines but not in A549, suggesting that RGD-mediated
integrin binding is not always essential for efficient entry of CV-A9.
Methods: Two cell lines, A549 and SW480, were used in the study. SW480 was the study object for the
integrin-independent entry and A549 was used as the control for integrin-dependent entry. Receptor levels
were quantitated by cell sorting and quantitative PCR. Antibody blocking assay and siRNA silencing of
receptor-encoding genes were used to block virus infection. Peptide phage display library was used to identify
peptide binders to CV-A9. Immunofluorescence and confocal microscopy were used to visualize the virus
infection in the cells.
Results: We investigated the receptor use and early stages of CV-A9 internalization to SW480 human epithelial
colon adenocarcinoma cells. Contrary to A549 infection, we showed that both CV-A9 and CV-A9-RGDdel internalized
into SW480 cells and that function-blocking anti-αV integrin antibodies had no effect on the binding and entry of
CV-A9. Whereas siRNA silencing of β6 integrin subunit had no influence on virus infection in SW480, silencing of
β2-microglobulin (β2M) inhibited the virus infection in both cell lines. By using a peptide phage display screening, the
virus-binding peptide identical to the N-terminal sequence of HSPA5 protein was identified and shown to block the
virus infection in both A549 and SW480 cell lines. HSPA5 was also found to co-localize with CV-A9 at the SW480 cell
periphery during the early stages of infection by confocal microscopy.
Conclusions: The data suggest that while αVβ6 integrin is essential for CV-A9 in A549 cell line, it is not required in
SW480 cell line in which β2M and HSPA5 alone are sufficient for CV-A9 infection. This suggests that the choice of
CV-A9 receptor(s) is dependent on the tissue/cellular environment.
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Background
Enteroviruses are common human viruses and endemic
in many developing countries. Although most enteroviral
infections are subclinical, they may cause a wide spectrum
of diseases including mild upper respiratory illness (com-
mon cold), febrile rash (hand, foot, and mouth disease and
herpangina), aseptic meningitis, pleurodynia, encephalitis,
acute flaccid paralysis (paralytic poliomyelitis) and neonatal
sepsis-like disease [1, 2]. Coxsackievirus A9 (CV-A9) is an
important member of Enterovirus B species (genus Entero-
virus B, family Picornaviridae, http://www.picornastudy-
group.com/) and one of the most prevalent and pathogenic
enteroviruses [1, 3]. Structurally CV-A9 is a small, non-
enveloped virus with a single-stranded RNA genome of
7452 nucleotides. The virus particle is composed of four
structural proteins (VP1-4). VP1, VP2 and VP3 are located
on the surface of the viral capsid, whereas VP4 faces the in-
ternal surface [4, 5]. A specific feature of the CV-A9 VP1
capsid protein is the C-terminal Arg-Gly-Asp (RGD) tri-
peptide motif through which the virus interacts with αV
integrins in vitro and on the cell surface [4, 6].
Interaction with the cell surface is the primary event
in the infectious viral entry. More than ten protein re-
ceptors are known to mediate the enterovirus entry, and
it is generally believed that the binding of an enterovirus
to the cell surface is mediated by the associations of one
or more protein receptors and/or non-protein attach-
ment factors [7, 8]. Successful cellular infection is thus
dependent on both the attachment factors that may act
as “sticky surface” and true protein receptors that con-
tribute to the binding of a virus to the cell surface and
intracellular transport of virus particles [9]. Many en-
teroviruses are capable of using several receptors for the
cell binding, and/or cellular entry [10–12] but with the
exception of Coyne and Bergelson study, it is not really
known how different receptors interact during the in-
ternalization process.
RGD-binding integrins include five members of αV
integrins (αVβ1, αVβ3, αVβ5, αVβ6 and αVβ8), two β1
integrins (α5β1 and α8β1) and the integrin αIIbβ3, and
share the ability to recognize ligands, which contain the
RGD tripeptide motif. There are four enterovirus types
that possess an RGD motif in the VP1 protein [12] of
which CV-A9 has been shown to bind in vitro to αVβ3
and αVβ6 integrins [13, 14]. Besides integrins there are
other cell surface molecules that have been suggested to
play a role in the CV-A9 infection. For example, β2-
microglobulin (β2M, CD59), a major histocompatibility
complex (MHC) class I heavy chain associated protein, and
heat shock 70 kDa protein 5 (HSPA5 protein, also known
as BiP or glucose-regulated protein 78 kDa, GRP78) have
been shown to mediate the entry of CV-A9 [15–17]. Earlier,
fluorescence resonance energy transfer (FRET) analysis sug-
gested that the αVβ3 integrin and HSPA5 colocalize on the
surface of green monkey kidney (GMK) cell line. This led
to a hypothesis in which these receptors function in the
binding of CV-A9 while β2M plays a role in the internaliza-
tion step [16–18]. More recently, we have shown that CV-
A9 possesses a high affinity only to the αVβ6 integrin and,
therefore, have suggested it to be the primary binding/at-
tachment receptor for the virus in A549 human epithelial
lung carcinoma cell line [13]. The structural and functional
features of the binding of αVβ6 integrin to CV-A9 have re-
cently been demonstrated in vitro implying that the αVβ6
integrin acts as the binding receptor for the virus and that
the virus binding to its integrin receptor does not induce
uncoating and, further, viral RNA release [19]. Thus, there
must be other molecules that mediate CV-A9 internaliza-
tion and entry.
In this study, we used the human epithelial colon
adenocarcinoma cell line (SW480) to analyze the cellular
binding and the infectious entry of CV-A9. We provide
evidence that β2M and HSPA5 are important in CV-A9
entry independently of the RGD-motif and αV integrins.
Methods
Cells and viruses
Human epithelial lung carcinoma (A549) cell line was
obtained from American Type Culture Collection (ATCC).
Human colorectal adenocarcinoma cells (SW480) [20] were
from Dr. Stephen Nishimura (UCSF, USA). A549 and
SW480 cells were maintained in DMEM and Ham’s F12
media, respectively, supplemented with 10 % foetal calf
serum (FCS) (or 1 % for virus infections) and gentamycin.
Coxsackievirus A9 (CV-A9, Griggs strain) [4, 21] and
CV-A9-RGD-mutant (CV-A9-RGDdel) [22] were from
laboratory collections. Viruses were propagated in A549
cells and purified as described previously [13, 23].
Antibodies and proteins
CV-A9 antibodies were from laboratory collections
[24, 25]. The function-blocking antibodies were against in-
tegrin αV (L230; ATCC), integrin αVβ3 (MAB1976Z;
Chemicon®), integrin αVβ5 (MAB1961Z; Chemicon®),
integrin αVβ6 (MAB2077Z; Chemicon®), integrin β1
(MAB2253; Chemicon®) and integrin α5β1 (MAB1969;
Chemicon®). Antibodies to β2-microglobulin were from
Santa Cruz Biotechnology (sc-51509). The rabbit antibody
to HSPA5 protein (sc-13968) was from Santa Cruz. Alexa
Fluor (AF) 488-, 546-, and the 568-labelled anti-mouse
and anti-rabbit secondary antibodies were from Molecular
probes. The horseradish peroxidase (HRP)-labelled anti-
rabbit secondary antibody was from Pierce. In all im-
munofluorescence experiments, the nuclei were stained
with Hoechst 33342 (Sigma-Aldrich). Purified integrin
αVβ3 was obtained from BioMarket Ltd. (catalog item 01-
INT-4). Integrin α5β1 was obtained from Chemicon®
(catalog item CC1052). Integrin αVβ6 was produced and
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purified in Chinese hamster ovary (CHO) cells as de-
scribed previously [26].
Flow cytometry
The expression of integrin αVβ6, αVβ3 and β1 on the
SW480 cell surface was analyzed by flow cytometry
using specific monoclonal antibodies as previously de-
scribed [13].
Quantitation of integrin expression in A549 and SW480
cell lines
Total mRNA levels of integrin subunits β3, β6, and β1
were analyzed by quantitative reverse transcription-PCR
(RT-qPCR) as previously described [27].
Antibody blocking and in vitro binding assays
The methods have previously been described [13, 27]. In
short, confluent cell monolayers (SW480 or A549 cells)
were washed with a serum free cell medium before
1.5 μg of function-blocking αV-, αVβ5- and β1-integrin
antibodies or anti β2-microglubulin (β2M) were added
(dilutions were made in a serum free cell medium con-
taining 1 mM MgCl2). After incubation in RT for 1 h,
unbound antibodies were removed by washing and cells
were incubated on ice for 1 h after the addition of the
diluted virus. The virus dilution was set to achieve 10 %
efficiency of infection in untreated cells. Unbound vi-
ruses were removed and infection was continued for 6 h
before fixation (4 % formalin in PBS), permeabilization
(0.1 % Triton-X100 in PBS) and staining (dilutions made
in 3 % BSA in PBS) with virus-specific and secondary
AF 488-labeled antibodies. Nuclei were stained with
Hoechst and the ratio of the virus-specific signal to the
total cell number was determined with Victor3 multilabel
counter (Wallac, Finland). The cells infected in the absence
of blocking antibodies were used as the positive infectivity
control (100 % infection), and the mean was calculated
from six parallel samples from three independent experi-
ments. The maximal blocking effect was determined by
using different concentrations (0–4 μg) of αV-integrin
blocking antibodies in A549 cells where the CV-A9 infec-
tion depends on the integrin binding. The same experiment
was performed with SW480 cells. In all data, error bars in-
dicate standard deviation counted from 3 to 6 samples from
three independent experiments and Anova single factor
analysis was used to calculate the statistics.
In the in vitro binding method a solid-phase integrin
binding assay was employed where the 96-well plate
(Costar High Binding) was first coated with 300 ng
integrins or BSA (a negative binding control). Wells
were then blocked with 3 % BSA for 1 h. Following the
addition of 0–200 ng of viruses, the plate was incubated
at RT for 30 min and washed with the coating buffer
after which the virus-specific antibody was added. After
a 1 h incubation at RT, the wells were washed and the
secondary anti-rabbit horseradish peroxidase conjugate
(HRP; Pierce) was added. The wells were incubated for
45 min at RT, stained with H2O2, and the absorbance
was read at 450 nm using Victor3. The mean was calcu-
lated from two parallel samples, range was calculated and
the experiment was repeated twice with similar results.
Receptor siRNA silencing and cell viability assay
In the receptor siRNA silencing assays, two individual
siRNA molecules (Qiagen) for each gene were used
(Additional file 1: Table S1). To transfect SW480 cells in
96-well plates, 1 pmol siRNA in 25 μl H2O was mixed
with 0.4 μl siLentFect (Bio-Rad), diluted in a serum
free medium and the wells were incubated at room
temperature for 30 min. After incubation, 25,000 SW480
cells were added in the cell medium supplemented with
7 % serum and cultured for two days at 37 °C in 5 % CO2.
The transfection conditions were optimized by transfect-
ing the cells with siRNA targeting glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and measuring the
GAPDH enzyme activity with a KDalert GAPDH Assay
Kit (Applied Biosystems). The virus inoculations aiming at
10 % efficiency of infection in untreated cells and antibody
staining steps were performed as described above. The cell
viability assay was performed according to manufacturer’s
instructions as previously described [27]. Cells without
CV-A9 served as a negative control and positive controls
include non-transfected, mock-transfected and scramble-
transfected cells.
Phage display screening
Phage display screening with a peptide library displaying
CX8C decapeptides (where X is any amino acid) was
performed as previously described [28, 29]. Briefly, puri-
fied CV-A9 (50 μg ml−1 in PBS containing 0.5 mM
MgCl2) was used to coat the wells on a Nunc Maxisorp
96-well plate. Specifically bound phages were eluted from
the wells and used to infect K91kan Escherichia coli. Two
consecutive rounds of panning were performed in the same
manner. Individual cell clones were subjected to colony se-
quencing in which cell mass was directly used as template
for PCR. During the denaturation step, cells are lysed re-
leasing the nucleic acid for amplification. Primers 5′ and 3′
to the peptide insertion site of the phage were used: the for-
ward primer was 5′-TAA TAC GAC TCA CTA TAG GGC
AAG CTG ATT AAC CGA TAC AAT-3′ and the reverse
primer 5′-CCC TCA TAG TTA GCG TAA CGA TCT-3′.
Sequences were compared against SwissProt database using
the FASTA program.
Peptide blocking assay
CV-A9 was mixed with synthetic ESPLSLVA (20 μM
200 μM and 5 mM) or RRRGEL peptides (5 mM) and
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incubated for 30 min. Both peptides and virus were di-
luted into PBS with 1 mM MgCl2. The RRRGEL-peptide
was used as a negative control because it does not block
CV-A9 infection [30]. After incubation, CV-A9 was
added onto the cells in the presence of peptides and in-
cubation was continued for another 30 min on ice. In-
stead of using MOI value, the virus amount was set to
achieve 10 % efficiency of infection in untreated cells.
Unbound viruses were removed, a pre-warmed infection
medium was added and the plate was transferred into
37 °C for 6 h. The cells were then fixed, permeabilized
and stained with the virus specific antibody and second-
ary AF 488-antibody. Nuclei were stained with Hoechst
and the virus and Hoechst signals were measured with
Victor3 multilabel counter. The cells incubated without
peptide were used as a positive infection control and
error bars indicate standard deviation counted from four
independent samples. Anova single factor analysis was
used to calculate the statistic and P < 0.05 was consid-
ered as a significant result. The experiment was repeated
twice with a similar outcome.
Confocal imaging
In all endocytosis assays, SW480 cells were grown on
cover slips in the wells of 24 well plate overnight at 37 °C
after which the plate was transferred onto ice and cells were
infected with the virus aiming at 40-60 % efficiency of infec-
tion. The infection was followed at 37 °C from 0 min up to
6 h, after which the cells were fixed and permeabilized (ex-
cluding the 0-min time period). Antibody staining was con-
ducted at room temperature by using specific antibodies
diluted in PBS with 3 % BSA. The plate was incubated at
RT for 1 h in the presence of primary antibodies after which
the cells were washed and AF-conjugated secondary anti-
bodies were added. After 30 min incubation at RT, the cells
were washed and nuclei stained with Hoechst 33342. Fixed,
permeabilized and immunostained cells were then mounted
on microscope slides in Mowiol 4–88 (Calbiochem-Nova-
biochem), 25 % glycerol, 0.1 M Tris-HCl, pH 8.5, contain-
ing Dabco 25 mg ml−1 (Sigma-Aldrich) and examined with
Zeiss LSM510 META confocal microscopes using a Plan-
Apochromat objective (63x oil). Colocalization analyses
(automatic thresholding after background subtraction,
Costes P-value calculation with 100 iterations) of selected
image stacks were performed with BioImageXD software
[31]. Scale bars are shown in the figures.
Results
CV-A9 and genetically modified RGD-deficient CV-A9
infect SW480 cells
Previously, it has been shown that infection of CV-A9 into
A549 cells is dependent on integrin αVβ6 [27]. To study
CV-A9 infection in a cellular model in which αVβ6 is not
expressed, we chose to use human colon adenocarcinoma
cells (SW480) [20]. It was reported by plaque titration assay
that CV-A9 infects SW480 cells only after transfection with
the cDNA copy of the β6 integrin subunit and overexpres-
sion of the corresponding protein [14]. However, the recent
paper by Gianni et al. [32] shows that there are several lines
of SW480 cells, some of which express αVβ6 and some
which do not. Therefore, the integrin expression profile of
SW480 cells used in this study was analyzed by flow cytom-
etry using antibodies specific to integrin β1-, αVβ3- and
αVβ6 (Fig. 1a). Integrin β1 subunits were highly expressed
whereas αVβ3 and αVβ6 integrin were not detected or
Fig 1 CV-A9 infection in the SW480 cell line is independent of an RGD and αV-integrins. a Fluorescence from flow cytometric analysis of integrin
expression. SW480 cells were incubated with integrin specific monoclonal antibodies against β1, αVβ3 or αVβ6 (cell controls as shown in a white
plot were incubated with a secondary antibody) and 10,000 cells were measured in each sample. The data was analyzed by the Cyflogic program
and the area of positive signal is indicated in a white plot. In the case of αVβ3 the white area is shadowed by the negative dark background.
Standard threshold values were used in the assays. b The ratio (SW480/A549) of integrin mRNA levels measured by quantitative PCR is indicated.
c Immunofluorescence images of SW480 cells infected with the wild type CV-A9 and with the RGD-deletion mutant (CV-A9RGDdel). Antibodies
specific to CV-A9 (green) were used. The nuclei (blue) were stained with Hoechst. The scale bar = 20 μm
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were expressed to a much lesser extent in the SW480 cells
than in the A549 cells [13]. This is in agreement with the
previous reports where the SW480 cell line was used
[14, 33, 34]. The mRNA levels of β1- (used as a positive
control), β3- and β6-subunits were also measured by
quantitative PCR (qPCR) and the results were com-
pared with the mRNA levels in the A549 cell. The re-
sults are shown in Fig. 1b as a percentage of the mRNA
levels in SW480 to A549 cells [27]. Corresponding
mRNAs of β3 and β6 integrin subunits were present in
the SW480 cells but to a much lesser extent than in the
A549 cells (Fig. 1b). The expression level of β6-subunit
in SW480 was only 9 % of the level detected in the
A549 cells. The data indicate that αVβ3 and αVβ6 are
only weakly expressed on the surface of SW480 cells,
which is also in line with another study in which foot-
and-mouth disease virus was studied in SW480 cell line
[35]. To further demonstrate that CV-A9 infects these
SW480 cells independently of an RGD-mediated integrin
binding, we infected both the prototype CV-A9 (Griggs
strain) and CV-A9-RGDdel, a virus mutant lacking the
RGD motif [13, 22], into SW480 cells, and followed the in-
fection by using cell imaging techniques. Figure 1c shows
that CV-A9-RGDdel is capable of entering SW480 cells
similarly to CV-A9.
Anti-integrin antibodies do not block CV-A9 infection in
SW480 cells
To exclude the possibility that low level of αV-integrin
expression (undetectable by cell sorting analysis in Fig. 1a)
in SW480 cells could explain the reduced CV-A9 infec-
tion, the integrin-independent infectivity of CV-A9 was
further analyzed by using anti-integrin blocking antibodies
(Fig. 2). As expected, anti-αV antibodies significantly
(P = 1.8–2.3 × 10−5) blocked the CV-A9 infection in the
a
b
c
d
Fig. 2 RGD-binding integrins are not required for the CV-A9 infection
in the SW480 cells. a Blocking of the CV-A9 infection with antibodies
against αV, αVβ5 or β1. The ratio of cells exhibiting a fluorescent signal
specific for the virus signal to Hoechst-stained nuclei was determined
by a Victor3 multilabel counter. Cells infected in the absence of integrin
antibodies (panel on the left) were used as a positive infectivity control
(infectivity set to 100 %). Error bars indicate standard deviation counted
from three independent experiments with 6 parallel samples.
Significance is indicated with an asterisk; *P < 0.05, **P < 0.01,
***P < 0.001. NS = not significant. b αV-antibody blocking in the
SW480 and A549 cells. Error bars indicate standard deviation counted
from 3 to 6 samples from three separate experiments and significant
reduction is indicated with an asterisk; ***P< 0.001. c Fluorescence from
cytometry analysis. SW480 cells were incubated with the integrin specific
monoclonal antibody against α5β1 and secondary antibody and the cell
control shown in a white plot was incubated only with a secondary
antibody. The result was analyzed by the Cyflogic program. d The
integrin binding assay with αVβ6, αVβ3, α5β1 or BSA (as a control).
CV-A9 was stained with polyclonal primary and secondary antibodies.
The range from the two parallel samples is shown
Heikkilä et al. Virology Journal  (2016) 13:171 Page 5 of 10
A549 but not in the SW480 cells (P = 0.2–0.6), while
antibody blocking of integrin αVβ5 and β1 did not re-
duce the infectivity (Fig. 2a-b). In addition, α5β1 did
not bind to the virus in in vitro assay although it was
highly expressed in SW480 cells (Fig. 2c-d). These data
together with CV-A9/CV-A9-RGDdel infectivity results
a
b
c
Fig 3 β2-microglobulin (β2M) is essential for the CV-A9 infection. a The siRNA-transfected SW480 cells were cultured for 48 h and then infected
with CV-A9. The infection was followed for 6 h and visualized by CV-A9-specific antibodies. The ratio of the AF 488 signal to the Hoechst (nuclei)
signal was considered as the measure of efficiency of the infection. The experiment was repeated five times with mean values calculated. The error bars
indicate standard deviation and the cut-off values were calculated as positive control mean ± 2 × SD. Positive control includes non-transfected,
mock-transfected and scramble-transfected cells. b The cell viability was checked by staining the cells with Hoechst and Sytox Orange. The
cells treated with 10 mM methyl-β-cyclodextrin (MBC) were used as “cell death” cytotoxicity controls. c SW480 and A549 cells were incubated
in the presence of a function blocking β2M antibody. The infection % was calculated as a ratio of the virus signal to the Hoechst signal. The
cells infected with CV-A9 in the absence of the antibody were used as positive infection controls (100 % infection). Error bars indicate the
standard deviation from three independent experiments with 4–6 parallel samples and the significance reduction in infectivity is indicated
with an asterisk. (P = 5.6 × 10−5 in SW480 cells and P = 2.1 × 10−5 in A549 cells)
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suggest that the CV-A9 entry into SW480 cells occurs
in the absence of αV integrins.
Receptor siRNA assay and antibody blocking of
β2-microglobulin
An siRNA panel against known picornavirus receptor
proteins was developed to identify receptors that would
mediate CV-A9 infection in SW480 cells [27] (Additional
file 1: Table S1). Two individual siRNA molecules for each
target gene were used. As shown in Fig. 3a, the most ef-
fective inhibition of the CV-A9 infection in the SW480
cells was obtained by using the siRNA targeted against
β2-microglobulin (β2M), which is in line with the pre-
vious results obtained using the A549 cells [27]. As ex-
pected, none of the RGD-binding integrins had an
effect on the CV-A9 infectivity in the SW480 cell line
while in the A549 cells the silencing of the αVβ6 integ-
rin blocked the CV-A9 proliferation [27]. To evaluate
the viability of the cells after the siRNA transfections,
the cells were stained with the dead-cell indicator Sytox
Orange. Methyl-β-cyclodextrin (MBC) was used as a
cell death marker because at 10 mM concentration this
inhibitor is lethal to the cells. None of the used siRNAs
showed cytotoxicity indicating that the observed changes
in the virus proliferation were due to the silencing of a
specific gene, and not due to the overall effects on the cell
viability (Fig. 3b).
The role of β2M in CV-A9 entry into SW480 cells was
further analyzed by using β2M antibodies. As shown in
Fig. 3c, β2M-antibodies had a clear inhibitory effect on
the CV-A9 infection in both the SW480 and A549 con-
trol cells. Antibodies significantly reduced the CV-A9
infectivity down to 10 % (P = 5.6 × 10−5) in the SW480
and 20 % (P = 2.1 × 10−5) in the A549 cell lines. Further-
more, the reduction in infectivity occurred in a dose-
dependent manner (Additional file 2: Figure S1). Thus, the
data suggest that β2M is essential for a successful CV-A9
infection in both SW480 and A549 cell lines.
Role of HSPA5 in CV-A9 infection
In addition to siRNA assay, a peptide phage display
screening was employed to identify peptides that bind to
the virus particles. The potential peptide binders of CV-
A9 were selected from the library of cyclic, degenerate
CX8C peptides displayed on a filamentous phage particle
[28], and ten CV-A9 and CV-A9RGDdel-binding phages
were sequenced. Only a single peptide binder, ESPLSLVA,
proved to be a potential viral receptor candidate for CV-
A9, while the sequences of the other peptides did not align
with any known cellular virus receptors and were not
analyzed further (Table 1). Interestingly, ESPLSLVA re-
sides in the N-terminal sequence of the HSPA5 protein
(NM_005347.4) [36]. Previous studies have demonstrated
that the HSPA5 protein and CV-A9 co-immuno-precipitate
in cell lysates from green monkey kidney (GMK) cells and
antibodies against the protein block the CV-A9 infection
[17], suggesting a physical interaction between HSPA5 and
the virus. The ability of ESPLSLVA peptide to prevent the
virus infection was hence tested. In the peptide blocking
assay where high quantities of ESPLSLVA peptide was used
the CV-A9 infection in the SW480 cells was significantly
(P = 4.0 × 10−5, respectively) blocked by the peptide while
the control peptide did not affect infectivity (Fig. 4a). Inter-
estingly, HSPA5 peptide blocked CV-A9 infection in both
SW480 and A549 cell lines in a dose-dependent manner,
which suggests that HSPA5 possesses a general role in
CV-A9 infection (Additional file 3: Figure S2).
To further study the role of HSPA5 in CV-A9 infection,
we performed experiments by using immunofluorescence
confocal microscopy to localize CV-A9 and HSPA5 during
the early stages of the virus infection. HSPA5 protein was
visualized by antibody staining in the absence of the virus
in both non-permeabilised and permeabilised cells to
demonstrate that it was expressed on the surface of the
SW480 cells (Fig. 4b). The distribution of HSPA5 was
drastically different between the infected and non-infected
cells (Fig. 4b-c). The HSPA5 protein accumulated in vis-
ible spots (at 0 min), which partially co-localized (29 %)
with CV-A9. This indicates early interaction of the virus
with the receptor on cell surface. Moreover, after 5 min
post-infection, a clear co-localization (40 %) between the
HSPA5 and CV-A9 was detected at close vicinity to the
inner surface of plasma membrane, further suggesting that
HSPA5 has a role in the CV-A9 attachment to the cell sur-
face and in the early stage of the internalization. In conclu-
sion, the data suggest that HSPA5 acts both in the
attachment and entry stages of CV-A9 in the SW480 cells.
Discussion
In this paper we used human colon adenocarcinoma cell
line and demonstrate that both the native CV-A9 and its
RGD-deletion mutant (CV-A9RGDdel) internalize into
SW480 cells (Fig. 1). In addition, anti-integrin function-
blocking antibodies were not capable of blocking the
CV-A9 infection of SW480 cells (Fig. 2). Thus, it is likely
Table 1 Peptide phage display panning using CV-A9 and
CV-A9-RGDdel as targets
CV-A9 CV-A9-RGDdel Non-specific
ESPLSLVA (1) LSWWSRKW (1) NWWSPVGV (1)
WWGIWMQE (1) WWAIWMQE (1) GWFKWGLW (1)
NLWGFWFP (2) LWWQIWDG (4) RPWPFWWQ (2)
PWWWGRNV (6) PWWWGRNV (3) FLGFPHWV (1)
WIWAWRSS (1) LGRWWWWS (2)
GWLWPGWF (1)
LQFSFLGF (2)
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that CV-A9 infection of the SW480 cells is independent
of the RGD-binding αVβ3 and αVβ6 integrins, which
have previously been suggested to play a role in CV-A9
infection in other cell lines. These data raised the question
as to which cellular receptors mediate CV-A9 infection in
SW480.
CV-A9 possesses an RGD motif in the C-terminus of
the VP1 capsid protein through which the virus has been
a
b
c
Fig 4 Co-endocytosis of HSPA5 with CV-A9. a The peptide blocking assay. The infectivity of CV-A9 was blocked by the ESPLSLVA peptide and
RRRGEL was used as negative control. Cells were fixed six hours post-infection, permeabilized and the virus was stained with specific antibodies.
Nuclei were stained with Hoechst and the infectivity was measured with Victor3 multilabel counter. Error bars indicate the standard deviation
from four independent samples and significance P = 4.0 × 10−5 is indicated with asterisk (***) or stated as not significance (NS). b Confocal
imaging of abundance of HSPA5 on the surface of SW480 cells (non-permeabilized cell) and in the cell interior (permeabilized cell). Non-infected
cells were stained with the HSPA5 specific antibody shown in red. c Co-internalization of CV-A9 and HSPA5. The cells were stained with virus-
specific (green) and HSPA5-specific (red) antibodies in non-permeabilized (0 min) cells to show the cell surface binding or in permeabilized cells
(5 min) to show the CV-A9/HSPA5 internalization. The nuclei were stained with Hoechst (blue). Co-localization of CV-A9 and HSPA5 is visualized
by yellow color in the merged images. Scale bars are 10 μm
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shown to bind αVβ3 and/or αVβ6 integrins in vitro
[13, 14, 22]. However, it has also been demonstrated
that the virus is capable of entering cells in an RGD-
independent manner, i.e. removal of the RGD motif
does not interfere with virus infection in certain cell lines
[6, 22]. However, the mechanism or mediators have
remained unknown. CV-A9 infection is also dependent on
attachment factors or co-receptors. An infection model
using green monkey kidney cell line has been proposed
[17] by which CV-A9 utilizes the αVβ3 integrin as its pri-
mary attachment receptor and HSPA5 as its co-receptor.
According to this model, αVβ3 integrin and HSPA5 medi-
ate CV-A9 attachment while HSPA5 cross-links MHC I
concentrating the molecules at the same location on the
cell surface. In contrast, we have recently suggested that
integrin αVβ6 acts as a high affinity receptor for CV-A9 in
A549 cells [13, 27], and it may thus function solely as a
binding receptor. We also demonstrated that β2M con-
fines the virus to the peripheral regions of the A549 cells
[27], which was also the case in SW480 cells (this study).
This suggests that β2M has a role either in the attachment
or in the early stage of the internalization regardless of
integrins.
The results from the phage display screening and pep-
tide blocking assay propose that CV-A9 also interacts
with the HSPA5 protein on the SW480 cell surface,
which thus seems to serve as a true protein receptor for
the virus (Fig. 4). While HSPA5 resides primarily in the
endoplasmic reticulum [37], it is also expressed on the
surface of various cell types [17, 38, 39]. Indeed, Borna
disease virus (BDV) interacts with surface-exposed HSPA5
through the GP1 capsid protein [40], and antibodies di-
rected against the N-terminus of HSPA5 protein have also
been shown to inhibit the binding and infection of the den-
gue virus serotype 2 [41]. Interestingly, HSPA5 seems also
to be effective in A549 cell line (Additional file 3: Figure S2)
where integrin αVβ6 is required for infectivity [27]. Given
that HSPA5 possesses a role in the entry stage of different
viruses, it may be a common factor in cellular endocytosis
of many viruses.
So far, most cellular studies related to CV-A9 have
been carried out in cancerous cell models in which the
receptor expression may differ from native cells. It is
hence possible that when infecting humans, CV-A9 uses
different receptors in a tissue-specific manner, which al-
lows the virus to survive in a multicellular environment.
Because many enteroviruses use several receptors for the
cell binding, and/or cellular entry [10–12], it is tempting
to speculate what happens in clinical CV-A9 infection.
Since the RGD motif is conserved in clinical CV-A9 iso-
lates [42] it is likely that RGD-αV-integrin interaction
plays a significant role in initiating CV-A9 life cycle in
multicellular environment. However, the role of integrin
may be solely in binding the virus to the cell surface.
We have previously suggested that integrin αVβ6 is high
affinity binding receptor to CV-A9 [13, 19], but it seems
that virus does not uncoat upon integrin binding [19]
and it is not internalized with the integrin receptor [27].
Thus, other receptors are needed for the internalization
process. It is possible that when in contact with epithe-
lial cells, CV-A9 binds to αVβ6 integrin via its RGD
motif that concentrates the virus on the cell surface, and
interaction with the HSPA5 and β2M proteins further
mediate the virus internalization. HSPA5 and β2M may
play central roles in CV-A9 infection because they are
ubiquitously expressed in most cell types [43].
Conclusions
We conclude that CV-A9 infection in SW480 cells is
not dependent on αV integrins, but requires β2M and
HSPA5. The data suggest that CV-A9 may use alternate
receptor(s) in different cellular environment, and may
partially explain wide tropism and pathogenicity of this
enterovirus type. The data also suggest that β2M and/or
HSPA5 may possess a general role as a viral receptor.
Additional files
Additional file 1: Table S1. The list of siRNA used in the study.
(PDF 209 kb)
Additional file 2: Figure S1. CV-A9 infection is blocked dose-dependently
by β2M antibody in SW480 and A549 cell lines. Significance reduction in virus
infectivity is shown with an asterisk (** < 0.01; *** < 0.001) and error bars
indicate standard deviation counted from four parallel samples. (PDF 61 kb)
Additional file 3: Figure S2. In A549 and SW480 cells, CV-A9 infection
is significantly blocked by peptide in a dose-dependent manner. Significant
reduction is shown with an asterisk (* < 0.05) and error bars indicate standard
deviation counted from four parallel samples. (PDF 6 kb)
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